Answers are grounded in this paper and cite their sources.
Background and objective: Gene-edited stem-cell products can address the causal biology of selected monogenic disorders, but their benefit depends on more than the proportion of alleles edited. The edited cells must retain self-renewal or tissue function, produce the intended phenotype, and remain genomically stable after administration. This review examines the evidence on gene-edited hematopoietic stem and progenitor cells (HSPCs), induced pluripotent stem cells (iPSCs), and their derivatives, focusing on editing precision, cellular fitness, potency, manufacturing, and long-term risk. Methods: This narrative review synthesizes mechanistic, preclinical, clinical, manufacturing, and regulatory literature, with emphasis on 2022 to November 2026 and on earlier pivotal work where needed. Evidence is organized thematically without a registered protocol or meta-analysis; clinical findings are distinguished from preclinical findings, and regulatory documents are interpreted according to jurisdiction and legal status. Key findings: Autologous ex vivo CRISPR-Cas9-edited CD34+ HSPCs provide the most mature clinical proof of concept, in sickle-cell disease and transfusion-dependent β-thalassemia. Base and prime editing widen the range of addressable variants and avoid a programmed double-strand break, but do not remove genotoxicity or delivery constraints. Translation is determined by on-target structural variation, off-target editing, DNA-damage responses, stem-cell fitness, clonal selection, conditioning toxicity, potency-assay relevance, manufacturing variability, and long-term surveillance. Conclusions: The translational objective is a genetically characterized, biologically competent, functionally potent, and acceptably safe cell product, not maximal editing efficiency in isolation. A product-centred strategy should link variant-level editing outcomes to cellular phenotype, durable engraftment or tissue function, clinical benefit, and proportionate long-term risk management.
No takes yet. Share an insight, caveat, or question.
Mohamed Reda (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: